The Initial Public Offering of Sudeep Pharma Limited was subscribed 1.42 times on the first day of bidding, demonstrating strong demand from retail and non-institutional investors for this IPO.

The issue received bids of 1,50, 09, 425 against the offered 1, 05, 64, 926 equity shares, according to data available on the stock exchanges.

Retail Portion and Non-institutional portion were subscribed 1.5 and 3 times respectively. Qualified Institutional Investors was subscribed 0.09 times.

The issue kicked off for subscription on Friday, November 21, 2025 and will close for subscription on Tuesday, November 25, 2025.

A day before the opening of the issue, Sudeep Pharma Limited had raised Rs 268.5 crore from anchor investors.

Some of the marquee institutions that participated in the anchor include- Mukul Agrawal of Param Capital (Sanshi Fund I), Prashant Khemka of  Whiteoak Capital Flexi Cap Fund, Akash Bhansali from ENAM, Prashant Jain of 3PIM India Equity Fund, SBI Healthcare Opportunities Fund, HDFC Mutual Fund – HDFC Innovation Fund, HDFC Mutual Fund – HDFC Manufacturing Fund, ICICI Prudential MNC Fund, Nippon Life India Trustee Ltd – A/C Nippon India Flexi Cap Fund, Axis Mutual Fund Trustee Ltd – A/C Axis Mutual Fund A/C Axis Multi Asset Allocation Fund, Aditya Birla Sun Life Trustee A/C Aditya Birla Sun Life Small Cap Fund, Mirae Asset Healthcare Fund MIRAH CFD, Motilal Oswal Large Cap Fund, Quant Mutual Fund – QSIF Equity Long Short Fund, Bandhan Small Cap Fund, UTI Healthcare Fund and Edelweiss Trusteeship A/C – Edelweiss Mutual Fund – Edelweiss Equity Savings Fund. 

Leading brokerage firms like Marwadi Financial Services and SBICap Securities have given a “Subscribe” rating to the issue highlighting the company is the largest producer of food-grade iron phosphate for infant nutrition, clinical nutrition and the F&B sector, in terms of production capacity, with a combined annual manufacturing capacity of 72,246 metric tons as of Jun 2025.

On the valuation front, at upper price band, the stock is trading at P/E multiple of 48.3x, based on post-issue capital. And given the leadership in the niche segment and future foray into high-growth businesses, the company is expected to show healthy profit growth aided by margin expansion.